Abingworth Bioventures 8 closes on $465m
Abingworth has held a final close for its new life sciences fund, Abingworth Bioventures 8 (ABV 8), on its $465m hard-cap, exceeding its $375m target.
More on Funds
2150 holds first close on €130m for debut fund
It plans to back 20 companies, offering equity cheques of up to €40m across the life of an investment
Tikehau closes T2 Energy Transition Fund on €1.1bn
Fund targets European companies operating in the clean energy production, low-carbon transport and energy efficiency segments
Skylake Capital holds first close, makes first deal
Debut fund leads a $3m round in UK-based deep-learning startup Mindtrace
Afinum back on road for ninth fund
Predecessor vehicle, which raised €410m in 2017, is now 86% deployed
Latest News
L Catterton acquires Birkenstock
German footwear company is reportedly valued at around €4bn and drew interest from several PE buyers
Hiro Capital invests $15m in three gaming studios
Funding will help the studios expand their development pipelines and accelerate global growth
Partners Group buys Parmaco from Terra Firma-led group
Vendors reportedly sought a valuation of between €800m-1bn for the company
P101 invests €6m in series-B for Bipi Mobility
P101 deploys capital from its Programma 102 and Italia 500 vehicles for the deal